BARD1 Life Sciences Granted R&D Tax Incentive Refund From ATO

May 26, 2019 11:20 PM PDT | By Team Kalkine Media
 BARD1 Life Sciences Granted R&D Tax Incentive Refund From ATO

BARD1 Life Sciences Limited (ASX: BD1) operates in the medical line of business. The company, based in Australia, is a medical technology company which aims to develop and commercialise non-invasive diagnostic tests towards detecting an early stage cancer. It focusses on detecting the disease at primary stages and save affected lives. The company has a proprietary tumour marker platform which has the capability to focus on diagnostic and therapeutic applications through different forms of cancer.

BD1 is working towards autoantibody tests to help in detecting breast, ovarian and lung cancers in their primary stages. Moreover, diagnostic projects are in pipeline towards addressing more forms of the disease.

On 27th May 2019, BD1 announced that it had been granted with $520,518 Research and Development (R&D) Tax Incentive refund for the financial year 2017/2018. This had been provided as per the Research and Development Tax Incentive refund by the Australian Taxation Office.

The scheme helps qualified Australian companies to invest in Research and Development activities across Australia. It offers cash rebates of 43.5% towards eligible R&D expenditure. BD1 had received a “R&D Tax Incentive – Advance and Overseas Finding Certificate” on 18th February 2019, from AusIndustry. It approved its R&D activities outside Australia as well. Hence, the company was eligible for the incentive for three financial years- 2017/18, 2018/19 and 2019/20.

In 2017/18, the company spent $1,196,594 towards research and development in Australia and overseas. The funds received would be utilised to further the development and commercialisation of the company’s diagnostics pipeline activities.

Besides the Tax Incentive refund, the company had also received an Issue Notification from the United States Patent and Trademark Office, earlier in May. This confirmed the patent “Regulation of BARD1 expression by non-coding RNA”. The patent claims were directed towards siRNA that focus and lessen the expression of the novel long non-coding BARD1 RNA molecule BARD1 9?L. The patent is due to expire on 12th July 2035.

As per the company’s quarterly report for the period ending 31st March 2019, the cash flow statement provided the below mentioned details:

During the half-year ended 31st December 2018, the company raised A$3.315 million through a non-renounceable Entitlement Issue and Shortfall Offer. Its cash position was recorded at $3.7 million. The BARD1-Breast cancer test portrayed positive results with high diagnostic accuracy to detect breast cancer and the same was for Ovarian cancer too. The company bagged two patents in USA (for Ovarian and breast cancer tests) and in China (For lung cancer tests).

The company’s total comprehensible loss for the half year ended 31st December 2018 amounted to $888,038. Total assets were $3,750,025 whereas liabilities stood at $389,721. The company’s total equity was recorded at $3,360,304. BD1 generated a total revenue of $27,567.

Share Price Information:

As on 27th May 2019, the stock is trading at A$0.020 (as at AEST: 2:56 PM), up by 5.263% as compared to its previous closing price. The company’s market cap is A$18.89m. The YTD return has been -13.64%.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.


Sponsored Articles


Investing Ideas

Previous Next